Compare Dr. Reddys with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs NOVARTIS - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB NOVARTIS DR. REDDYS LAB/
NOVARTIS
 
P/E (TTM) x 22.3 489.5 4.6% View Chart
P/BV x 3.3 28.4 11.8% View Chart
Dividend Yield % 0.7 1.6 43.9%  

Financials

 DR. REDDYS LAB   NOVARTIS
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
NOVARTIS
Mar-18
DR. REDDYS LAB/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs2,875758 379.3%   
Low Rs1,888579 326.1%   
Sales per share (Unadj.) Rs930.2228.4 407.3%  
Earnings per share (Unadj.) Rs117.431.7 370.0%  
Cash flow per share (Unadj.) Rs185.832.8 567.0%  
Dividends per share (Unadj.) Rs20.0010.00 200.0%  
Dividend yield (eoy) %0.81.5 56.1%  
Book value per share (Unadj.) Rs844.4297.1 284.2%  
Shares outstanding (eoy) m166.0724.69 672.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.62.9 87.5%   
Avg P/E ratio x20.321.1 96.3%  
P/CF ratio (eoy) x12.820.4 62.8%  
Price / Book Value ratio x2.82.2 125.4%  
Dividend payout %17.031.5 54.1%   
Avg Mkt Cap Rs m395,49616,505 2,396.2%   
No. of employees `00022.00.7 3,288.3%   
Total wages/salary Rs m33,5621,445 2,322.1%   
Avg. sales/employee Rs Th7,032.88,441.3 83.3%   
Avg. wages/employee Rs Th1,527.92,163.6 70.6%   
Avg. net profit/employee Rs Th887.71,173.1 75.7%   
INCOME DATA
Net Sales Rs m154,4825,639 2,739.6%  
Other income Rs m3,3751,718 196.4%   
Total revenues Rs m157,8577,357 2,145.6%   
Gross profit Rs m31,782-63 -50,851.2%  
Depreciation Rs m11,34825 44,853.8%   
Interest Rs m88955 1,607.6%   
Profit before tax Rs m22,9201,575 1,455.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,858792 487.4%   
Profit after tax Rs m19,500784 2,488.5%  
Gross profit margin %20.6-1.1 -1,856.1%  
Effective tax rate %16.850.3 33.5%   
Net profit margin %12.613.9 90.8%  
BALANCE SHEET DATA
Current assets Rs m111,1019,522 1,166.8%   
Current liabilities Rs m58,9733,296 1,789.2%   
Net working cap to sales %33.7110.4 30.6%  
Current ratio x1.92.9 65.2%  
Inventory Days Days7937 216.7%  
Debtors Days Days9428 331.4%  
Net fixed assets Rs m101,24546 220,097.8%   
Share capital Rs m830123 672.6%   
"Free" reserves Rs m139,4067,213 1,932.7%   
Net worth Rs m140,2367,336 1,911.5%   
Long term debt Rs m22,0000-   
Total assets Rs m224,65611,105 2,023.0%  
Interest coverage x26.829.5 90.8%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.70.5 135.4%   
Return on assets %9.17.6 120.1%  
Return on equity %13.910.7 130.2%  
Return on capital %14.922.2 67.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,67361 146,325.1%   
Fx outflow Rs m19,1043,630 526.3%   
Net fx Rs m69,569-3,570 -1,948.9%   
CASH FLOW
From Operations Rs m28,7041,610 1,783.0%  
From Investments Rs m-7,727687 -1,124.7%  
From Financial Activity Rs m-21,326-2,677 796.8%  
Net Cashflow Rs m-314-380 82.7%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.4 2.0 270.0%  
FIIs % 35.3 1.6 2,206.3%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 21.5 71.2%  
Shareholders   75,885 41,647 182.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   DIVIS LABORATORIES  WOCKHARDT  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Strong; HCL Tech and Tech Mahindra Top Gainers(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.6% while the Hang Seng is up 0.4%.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

My Top 10 Stocks for Accelerated Profits

Oct 18, 2019

Equitymaster's co-head of research and editor of Microcap Millionaires, Rahul Shah, talks to us about his market-beating system and his 10 best stocks to buy now. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Oct 24, 2019 10:15 AM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS